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CYCLOSPORINE (CsA) used with ste-
roids has been a major influence in the 
improved survival of patients undergoing 
orthotopic liver transplantation. The overall 
results of patient survival have been published 
elsewhere. I •2 Part of the increased survival 
rate is dependent on retransplantation for 
homograft failure. We report our experience 
of patient and homograft survival as well as 
major causes for graft failure. 
MATERIALS AND METHODS 
From May II. 1981. to March 7. 1983.43 patients 
ranging in age from 7'/2 months to 18 years received 57 
orthotopic liver homografts. Table I lists the indications 
for transplantation. Patients reported here have been 
assigned OT (orthotopic transplant) numbers. which 
allows one to follow and compare the course of anyone 
patient in previous or subsequent publications. Details of 
patient selection and immunosuppression have been 
described in detail e1sewhere.'-J Briefly. patients were 
given oral CsA (17.5 mgjkg) or an intravenous infusion 
of CsA (5 mgjkg) a few hours preoperatively. Intrave-
nous CsA was continued at 5 mg/kgjday. divided twice 
daily. until oral CsA could be begun at 17.5 mg/kgjday. 
divided twice daily. Most pediatric patients were given a 
burst of steroids beginning the day of surgery (100 mg 
methylprednisolone) and rapidly tapered to a baseline 
dose (20 mgjday of prednisone) 4-5 days postoperatively. 
This baseline steroid dose was further decreased pending 
the patient's clinical course. 
If clinical signs of rejection appeared. the immunosup-
pression regimen was modified. Initially. a single bolus of 
hydrocortisone (500-1000 mg) was given intravenously. 
If the patient showed only moderate improvement, a cycle 
of prednisone similar to that given immediately postoper-
atively was also begun. In addition. CsA doses were 
occasionally increased. monitoring clinical and laboratory 
evidence for nephrotoxicity. Whole blood CsA levels were 
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measured by high-pressure liquid chromatography' in 
patients transplanted since January 1983. and CsA doses 
were adjusted to achieve trough levels of 100-400 ngjml. 
Graft failures occurred when irreversible and pro-
gressive hepatic injury was noted by increases in bilirubin 
and hepatocellular and canalicular enzymes as well as' 
worsening prothrombin time. 
RESULTS AND DISCUSSION 
From 5/ II /81 to 3/7/83. 43 pediatric" 
patients received 57 hepatic homografts. 
Overall patient survival to 3/7/83 is 63% 
(27/43). Thirteen patients (30%) received. 
multiple transplants; 12 patients received two 
homografts. and I patient received three 
homografts. The overall patient survival of 
retransplanted patient is 38% (5/13). • 
Twenty-four overt graft failures occurred in 
the 57 homografts (42%). Of the 16 patients 
who died. transplantation in 6 patients took. 
place while the patient was moribund, and the ' 
patient expired shortly after surgery. Graft I 
function was assessed shortly prior to death. I 
Those six grafts are not included in graft«: 
failures. 
Causes of graft failure and contributing 
causes of graft failure are listed in Table 2. 
Although the primary cause of graft failure is 
given, other factors often contributed to graft 
injury. At times it was difficult to determine 
which was the dominant factor responsible 
graft failure. The most prominent patholog- . 
ical event found in the graft at retransplanta-
tion or autopsy helped determine the major 
factor. Infarction, rejection, vascular acci-
dents, and infection were the major causes of -
graft failures (Table 3). 
Infarction 
Hepatic infarction accounted for the loss of 
eight grafts (33%). All but two of these grafts 
never had adequate function and were rna 
by an immediate and continued postoperative 
enzyme elevation, often in the thousands. Bili-
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Indications for Pediatric Liver Transplantation 
Biliary atresia 18 
Metabolic 
Alpha-l-antltrypsin deficiency 7 
Glycogen storage Disease I 
Hereditary tyrosinemia 1 
Wilson's disease 2 
Sea blue histiocyte 
Biliary hypoplasia 4 
Chronic active hepatitis 3 
Familial cholestaSis 3 
Neonatal hepatitis 
Biliary obstruction 
Benign liver tumor 1 
Total 43 
'rubin also rose, and clotting studies worsened. 
Death occurred if retransplantation did not 
within 72-96 hr. Reasons for graft 
infarction were not clear because vessels were 
"all patent at retransplantation or autopsy. 
Possible factors for infarction might include 
of an already injured graft or 
damage to the graft during harvesting, trans-
port, or implantation. An example of the latter 
might be OT 279B. who suffered an intra-
operative cardiac arrest. The graft never func-
tioned well. 
Two patients, OT 232 and OT 240, had a 
onset of massive hepatic infarction. 
OT 232 had an absent inferior vena cava. 
Each had initial good function postoperatively 
but suffered subsequent fulminant hepatic 
. and death at 12 and 10 days, respec-
tively. Both grafts had patent vascular anasto-
i moses at postmortem examination. Both 
1IIPatiems, however. had preformed T-cell warm 
antibodies directed against the graft. Whether 
acute rejection was contributory to the infarc-
tion is purely speculative. 
... 
Table 3. Status of SUPViving Grafts 
Discharged survivors· 26 
Bilirubin < 1.5 mg/dl 24 
SOOT < 100lU 25 
Status 
Well 
Chronic rejection 
Mild rejection 
24 
2593 
·OT 246, not included. recently underwent a third trans-
plant and is still hospitalized. 
Rejection 
Rejection occurred as a major cause of 
graft failure in 29% (7/24) of grafts. In 
addition, it was a contributing factor in the 
failure of another 4 grafts. Pathological fea-
tures of rejection have been described else-
where.s-7 In most cases, rejection was mani-
fested by fever, malaise. hepatomegaly with 
induration of the graft. ascites. and vague 
abdominal discomfort. Bilirubin increased 
and canalicular enzymes increased. usually 
out of proportion to the hepatocellular 
enzymes. Generally an ominous prognostic 
feature has been the disappearance of bile 
ducts within the portal triadsY Clinically, 
rejection mimicked other disorders, especially 
biliary tract obstruction and portal vein occlu-
sion. If the patient did not respond to specific 
therapy directed toward rejection. the patho-
logical process could be determined with cer-
tainty only with specific investigations such as 
cholangiography and angiography, as well as 
biopsy. In addition, these clinical entities may 
not be exclusive of each other. and it is at least 
theoretically possible that they may contrib-
ute to one another. Such an example might be 
decreased hepatic blood flow during rejection 
Table 2. Causes of Graft Failure 
Failure (No.1 
(N - 241 Major Cause Contributing Cause 
.0-----------------------------------------------------------------------------Hepatic infarction (8) 
Rejection (7) 
-
Vascular accident (51 
Infection (4) 
• 
OT 265. 271A. 271B. 240. 
232.284A. 203A, 279B 
OT 216. 214A, 203B. 266A. 
229A. 246A. 2S0A 
OT 220. 259A. 273A, 267. 
214B 
OT 201.191,2598. 279A 
OT 232. 214B. 240.191 
OT 232. 259B. 266A 
OT 259A, 266A. 246A 
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causing vascular thrombosis and/or infec-
tion.8 
OT 266A had clinical and pathological 
evidence for chronic rejection while on 18 
mg/kg/day of CsA. Prior to retransplanta-
tion, CsA kinetics studies demonstrated poor 
oral absorption at that dose. Retransplanta-
tion occurred 57 days after the initial trans-
plant. Pathology of the initial graft demon-
strated severe rejection and a branch hepatic 
artery thrombosis. Cyclosporine was in-
creased to 29 mg/kg/day, achieving adequate 
blood CsA levels, possibly preserving good 
function of the second graft. No nephrotoxic-
ity was noted. This patient demonstrated the 
possible interplay of several pathological pro-
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cesses as well as the possible potential value o. 
measuring CsA levels. In addition, this patien: 
was representative of many of our patient~ 
who received higher than the standard CsA 
dose and appeared to tolerate it without overt 
nephrotoxicity. 
Vascular Accidents 
Vascular complications accounted for thl 
loss of 5 (21 %) grafts. OT 220A had no portai 
vein found at transplant, and the portal anas-
tomosis was made to the recipient's vena cava. 
The graft failed from portoprival flow. OT 
259A suffered both portal vein thrombosis 
and hepatic artery thrombosis; OT 267 throm-
bosed the hepatic artery; OT 273A had a 
OT :: 214 2 ~ yo. male 
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Fig. 1. Clinical course of OT 214. Note the late onset of rejection marked by rises in SGOT, GGTP, and 
Rejection persisted despite aggressive immunosuppression, culminating in ratransplantation on day 241. 
course of the second transplant was marked by rises in the ume laboratory studies. Steroid boluses did not alter 
the course. Postmortem examination confirmed the premortem diagnosis of portal vein thrombosis. Vertical bars 
during steroid therapy indicate large boluses of i.v. steroid. The CsA graph indicatesl.v. dosing by the solid bar and 
oral dosing by the open bar. 
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U1Il1UU""" of the portal vein and inferior vena 
and OT 214B had a thrombosed portal 
...... sf~1aK Vascular complications may have been 
in the failure of another 3 cases. 
The course of OT 214A and B is depicted in 
1. The first graft was lost to rejection, and 
second to a portal vein thrombosis. This 
was unusual because unrelenting 
"re:ie(:ticm occurred several weeks after achiev-
normal liver functions-later than most 
Despite continued high-dose ste-
the course of rejection was unaltered. 
patient became increasingly debilitated 
_""i"h high-dose immunosuppression. The clini-
I~f course and laboratory findings of rejection 
"and portal vein thrombosis were similar. We 
ve since changed our approach to patients 
with chronic rejection. Once it is determined 
'that rejection is irreversible through lack of 
response to increased immune suppression 
pathological evidence, retransplantation 
is considered earlier. The patient's immune 
suppression is decreased to avoid overimmu-
nosuppression. The surgery is often easier 
r<;"<1r~;y; vital structures already have been 
skeletonized and the patient is not debilitated 
from chronic overimmunosuppression. 
Infection leading to graft failure occurred 
in 4 (17%) patients and was a contributing 
in another 3 losses. In patients OT 201 
and OT 279A, biliary tract reconstruction 
may have been the initial inciting event, lead-
to biliary sepsis and graft failure. The 
second liver of OT 259B was grafted to vessels 
already infected with candida and Pseudo-
monas aeruginosa. OT 191 emphasized 
--Starzl's concept of septic hepatic gangrene.s 
The patient had a large fungal abscess. The 
homograft injured from rejection or vascular 
..insult is much more susceptible to infection I than one not injured. 
I ee~ati~ homograft loss was a frequent 
. I complIcatIon of transplantation. Acute he-
~atic infarction, rejection (despite the use of 
; ~sA ~nd steroids), vascular accidents, and 
, ~ mfectlOn were primary causes of graft failure. 
..farly retransplantation may be beneficial in 
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preventing patient death with initial graft 
loss . 
Surviving Grafts 
The current status of 27 surviving patients 
is listed in Table 3. One patient recently 
underwent a third transplant (not in the time 
frame discussed above) and will not be 
included in the following discussion. Of the 26 
remaining survivors, 24 (92%) have bilirubins 
under 1.5 mg/dl. Of the 2 patients with 
elevated bilirubins, OT 206 has chronic rejec-
tion and may require retransplantation; OT 
237 has mild rejection due to drastic lowering 
of immunosuppression because of an intesti-
nal lymphoma. OT 206 is the only patient who 
has an SGOT of > 1 00 IU. Daily prednisone 
dose averages 0.4 mg/kg/day, and the mean 
CsA dose is 15.5 mg/kg/day. Cyclosporine 
doses in patients transplanted prior to 9/82 
average only 10 mg/kg/day. Patients trans-
planted subsequently, however, have an aver-
age dose of 25.6 mg/kg/day. Generally, this 
dose is able to be decreased to 8-10 mg/ 
kg/day within the first postoperative year.9 It 
appears, therefore. that the vast majority of 
surviving grafts have excellent function. 
CONCLUSIONS 
Hepatic homograft failures occur fre-
quently (42%) and remain a major cause of 
morbidity and mortality in pediatric liver 
transplant patients. Graft infarction (33%), 
rejection despite the use of CsA and steroids 
(29%), vascular accidents (21%), and infec-
tion (17%) are major causes of graft failure. 
Attempts to control rejection may involve 
using higher doses of CsA than previously 
accepted, and children may tolerate larger 
oral doses with little nephrotoxicity. Despite a 
30% retransplantation rate, 92% of surviving 
grafts are associated with bilirubins of < 1.5 
mg/dl, indicating excellent function of surviv-
ing grafts. 
ADDENDUM 
Since submission of this manuscript, OT 
206 underwent successful retransplantation 
for chronic rejection. Her bilirubin and 
enzymes are within normal limits. 
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